Tenax Therapeutics, Inc. TENX
1.76 USD -0.08 (-4.31%)
Nov 4, 2026, 10:34 AM EST
1.76 Day range 1.88
1.31 52-week range 19.40
- YTD
- -85.56%
- 1 year
- -74.88%
- Market cap
- 65.87M
- EPS (ttm)
- -1.48
- Shares out
- 3.41M
- Forward P/E
- -1.06
- YTD return
- -85.56%
- 1-year return
- -74.88%
- Volume
- 433.93K
- Avg volume
- 5.66M
- Open
- 1.85
- Previous close
- 1.84
- Day's range
- 1.76 – 1.88
- 52-week range
- 1.31 – 19.40
- Beta
- 2.15
- Price target
- 16.30 (+825.8%)
- Earnings date
- Apr 1, 2024
30m +0.17 (+10.56%)
Key statistics
- Enterprise value
- 7.73M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.20
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -7.55M
- Total cash
- 9.38M
- Total debt
- 278.80K
- Return on equity
- -113.79%
- Short % of float
- 4.10%
- 50-day average
- 4.96
- 200-day average
- 3.94
Analyst view
Price target (mean) 16.30 +825.8% upside
Now 1.76
- Target (low)
- 7.00
- Target (mean)
- 16.30
- Target (high)
- 30.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy1
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Apr 1, 2024
Expected Apr 1, 2024. Consensus EPS estimate -0.4225.
Financials — quick view
TENX Revenue — quarterly 0
TENX Net income — quarterly -17.80M
TENX EPS — quarterly -0.35
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -1.38 | -0.19 | +1.19 | +86.23% |
| Aug 13, 2024 | Jun 1, 2024 | -1.99 | -1.83 | +0.16 | +8.04% |
| May 14, 2024 | Mar 1, 2024 | -2.40 | -3.12 | -0.72 | -30.00% |
| Apr 1, 2024 | Dec 1, 2023 | -8.15 | — | — | — |
| Nov 13, 2023 | Sep 1, 2023 | -7.20 | -6.40 | +0.80 | +11.11% |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 24, 2024 | Leerink Partners | init | — | Outperform |
| Feb 20, 2024 | Roth MKM | reit | Buy | Buy |
About Tenax Therapeutics, Inc.
Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- tenaxthera.com
News
Kaplan Fox Alerts Tenax Therapeutics, Inc. (TENX) Investors Who Suffered Losses to a Securities Class Action - Deadline is December 28, 2026 
TENX EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Tenax Therapeutics (TENX) Investors of Securities Class Action Lawsuit Deadline on December 28, 2026 
ROSEN, LEADING INVESTOR COUNSEL, Encourages Tenax Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TENX 
Pomerantz Law Firm Announces the Filing of a Class Action Against Tenax Therapeutics, Inc. and Certain Officers – TENX 
SHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against Tenax Therapeutics, Inc. (TENX) - Investors Who Suffered Losses Are Encouraged to Contact the Firm 
Securities Fraud Class Action Filed Against Tenax Therapeutics, Inc.: Glancy Prongay Wolke & Rotter LLP Announces Lead Plaintiff Deadline 
Securities Fraud Class Action Lawsuit Pending Against Tenax Therapeutics, Inc.: The Law Offices of Howard G. Smith Highlights Lead Plaintiff Deadline 
SueWallSt Reminds Tenax Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of December 28, 2026 - TENX 
TENX INVESTOR NOTICE: RGRD Law Announces that Tenax Therapeutics, Inc. Investors with Substantial Losses May Seek to Lead Class Action Lawsuit Before December 28, 2026 Deadline 
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Tenax Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TENX
Your note
Sign in to keep a note on TENX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DAVIDSON MICHAEL H | Director | Purchase | Aug 7, 2024 | 2,881 |
| PROEHL GERALD T | Director | Purchase | Aug 7, 2024 | 1,667 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BVF Inc. | 9.96% | 339,549 | 1.86M | Sep 29, 2024 |
| Vivo Capital, LLC | 6.11% | 208,333 | 1.14M | Sep 29, 2024 |
| VR Adviser, LLC | 6.11% | 208,333 | 1.14M | Sep 29, 2024 |
| Velan Capital Investment Management LP | 2.44% | 83,333 | 457.50K | Sep 29, 2024 |
| Adage Capital Partners GP L.L.C. | 2.44% | 83,333 | 457.50K | Sep 29, 2024 |
| Vestal Point Capital, LP | 2.44% | 83,333 | 457.50K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Price (T.Rowe) Health Sciences Fund | 0.78% | 26,472 | 145.33K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.30% | 10,217 | 56.09K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.18% | 5,984 | 32.85K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.14% | 4,708 | 25.85K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.07% | 2,326 | 12.77K | Sep 29, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.01% | 364 | 2.00K | Oct 30, 2024 |